Remove Food Remove IPO Remove Sale
article thumbnail

Croatian food retailer Studenac plans Warsaw, Zagreb IPO

Global Banking & Finance

GDANSK (Reuters) -Croatian food retailer Studenac is planning an initial public offering with plans to list on the stock exchanges of Warsaw and Zagreb, the company said on Thursday. The offer will consist of new shares and the sale of existing shares by current shareholders.

Food 52
article thumbnail

M&A Heats Up in the Bakery Market

Focus Investment Banking

It’s no surprise that bakery is one of the food industry’s most dependable performers. As a staple food, it’s insulated from fluctuations in household incomes and business cycles compared to the broader food and beverage industry. The bakery category is also incredibly resilient. The $75 billion U.S.

M&A 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Elevating Expertise: Senior Advisor Spotlight, Bob Bicksler

Focus Investment Banking

in $8B transaction), howstuffworks.com International (merged into NASDAQ company), Global Metro Networks, MetroNet (IPO), Performance Awareness Corp. IPO), and Megapath Communications. I draw on my own experience – for example, the “morning after” a sale and how to handle that. Believe it or not, that can be painful at first.

M&A 52
article thumbnail

Momentum Builds for Ophthalmology Recapitalizations

Focus Investment Banking

Traditional terminal exit routes for private equity-backed companies are to larger strategic acquirers (often public companies) and IPOs, where a private company becomes publicly traded. Pet food manufacturer Mars, for example, started acquiring larger veterinary organizations years ago. The theme is not entirely new, however.

article thumbnail

Cooley’s 2024 Life Sciences M&A Year in Review: M&A Slims Down in 2024, but Will Appetites Grow in 2025?

Cooley M&A

By 2030, more than 190 commercial drugs will lose patent exclusivity , putting at risk $236 billion in Big Pharma sales. This approach, combining M&A and initial public offering (IPO) preparations on parallel tracks, allows companies to maximize optionality in an uncertain market.

M&A 64